COVID-19 Therapeutics Provider Resources
This webpage is specifically intended for the medical community.
Click here to find locations offering treatments.
COVID-19 Therapeutic Support Team
As of November 2023, both Paxlovid and Lagevrio have transitioned to the commercial market and are available for purchase through usual mechanisms. Additionally, as of December 15, 2023, the San Bernardino County COVID-19 Therapeutic Program will come to a close. This means Therapeutics will no longer be available to order through San Bernardino County.
Please see “Provider Fact Sheet for Commercialization” for a brief overview regarding this transition.
Please see the COVID-19 Therapeutics Commercialization Transition Guide for more details about the federal transition.
Test to Treat
Overview of Test to Treat
The Test to Treat initiative is a program created by the federal government to bridge the gap between patients testing positive and receiving oral antiviral medication. The only treatments available in the Test to Treat program are Merck’s Lagevrio (Molnupiravir) and Pfizer’s Paxlovid. This initiative will also expand access and attempt to tackle equity discrepancies throughout the United States.
To locate Test to Treat sites near you please view COVID-19 Test to Treat Locator.
If you have any additional questions you can reach out to your Local Health Jurisdiction at SBCOVID19Therapetics@dph.sbcounty.gov.
Oral Antiviral Medication
The CDC has issued a Health Alert Network Health Advisory to update the healthcare providers and public health departments of the potential for recurrence of COVID-19 or COVID-19 rebound. Although, Paxlovid remains the first recommendation for early stage treatment of mild to moderate COVID-19 among persons at high risk for progression to severe disease.
COVID-19 rebound has been reported between 2-8 days after initial recovery and is characterized by the recurrence of COVID-19 symptoms or a new positive viral test after having tested negative. Current data has not shown any signs of severe disease or that an additional dose of Paxlovid is needed.
Healthcare providers are encouraged to report cases of COVID-19 rebound after Paxlovid treatment to Pfizer using Pfizer Safety Reporting and to FDA MedWatch.
Please refer to Official CDC Health Advisory for Paxlovid
Type: Oral antiviral
Target Population: COVID-19 patients 12 years of age and older with mild-moderate symptoms and are at high risk of developing severe COVID-19, including hospitalization or death.
Pfizer’s Renal Paxlovid
Type: Modified Dosing for the Oral Antiviral Paxlovid
Target Population: COVID-19 patients with moderate renal impairment, 12 years of age and older with mild-moderate symptoms and are at high risk of developing severe COVID-19, including hospitalization or death.
Renal Dosing Letter for Health Care Providers
Type: Oral Antiviral
Target Population: Adult COVID-19 patients with mild-moderate symptoms and are at high risk of developing severe COVID-19, including hospitalization or death. Also used for those who do not fall under the FDA authorization of alternative COVID-19 treatment options.
Providers should carefully review the fact sheet for healthcare providers (available both for Paxlovid and Lagevrio (Molnupiravir)) before prescribing either medication to ensure that the patient’s condition warrants treatment, that there are no drug interactions, and that there are contraindications to therapy.
Providers Eligible to Receive Therapeutics
Paxlovid and Lagevrio: Paxlovid and Lagevrio are no longer available for ordering through San Bernardino County. However, both products are available for commercial purchase through usual mechanisms for any providers looking to purchase this medication.
Follow the link below for the lists of all pharmacies that have inventory of Government purchased Paxlovid and Lagevrio COVID-19 Therapeutics Locator
Reporting for ALL COVID Therapeutics:
*The reporting requirements are only for product that was obtained from San Bernardino County
Volunteer Reporting Reference Guide:
Usage and Inventory for commercially purchased product will be voluntary. Providers are encouraged to report as often as possible in hopes to keep the therapeutic locator as accurate as possible. This locator will allow patients who are looking for treatment to find a local provider near them.
Questions regarding ordering process:
Americource Bergen (ABC) commercial distributor: